9th CELL THERAPY SYMPOSIUM

DEAR COLLEAGUES,

A year has passed since the last Cell-Therapy Symposium took place. Within this brief period of time, tremendous progress has been made at our clinic with view to CAR-T cell therapy: More than 250 patients have received this leading-edge treatment at our medical center.

Across the globe, more than 42,000 patients have undergone remarkably successful treatment regimens for acute leukemia, Non-Hodgin’s lymphoma, as well as for myeloma. In light of this substantial track record, current therapeutical algorithms applied to tackle
these diseases need to be revisited. 

This symposium is meant to put special emphasis on an in-depth comparison of bispecific antibodies and CAR-T cells; in conjunction with a survey of novel TCR-T cell therapies directed at solid tumors. Both the ongoing exploration and identification of novel targets, as well as the preclinical research necessary to further the development of immunogenic therapies will be themes of our scientific discussion.

We cordially invite all participating physicians, scientists and doctoral fellows to submit their respective abstracts, which will subsequently be presented as posters in the course of this two-day conference. Authors whose posters are deemed best, will be given the opportunity to elucidate their work in the form of a short presentation.

We are looking forward to welcoming you at our symposium.

With warm regards from Heidelberg

Michael Schmitt
Carsten Müller-Tidow
Peter Dreger

The participation is free of charge. This conference is certified by the Landesärztekammer Baden-Württemberg. Corresponding CME-credits are granted. 

To safeguard a proper organization of this conference, we ask participants to register through the following portal by 15 October 2025 — at the latest.

Kindly relay your scientific abstracts to: Marcel Pichal, M.A. marcel.pichal(at)med.uni-heidelberg.de